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Microvesicles are a recently described way of cell communication that has been
implicated in a number of biological processes, including neuroinflammation. Widely
investigated as biomarkers in oncology and neurological disorders, little is known of the
role of microvesicles in the pathogenesis of diseases such as multiple sclerosis (MS).
Several evidences suggest that pro-inflammatory microglia and infiltrating macrophages
release microvesicles that spread inflammatory signals and alter neuronal functions. We
review here available information on microvesicles, with a special focus on microglia and
macrophage microvesicles, in the pathogenesis of MS, and as potential biomarkers and
therapeutic targets.
Keywords: microvesicles, multiple sclerosis, exosomes, ectosomes, horizontal communication, biomarkers,
microglia
Introduction
Since its first steps neurobiology focused the most part of its efforts on trying to elucidate in great
detail the physiology of neuronswith very few attention about the other cell types (as awhole referred
as glia) because considered as important as just a glue for the neuronal networks assembly and
stabilization (1).
Growing attention has been gradually given to glial cells since the demonstration of the multiple
roles they have, not only in the maintenance of the brain environment but also in crucial steps of
the synaptic transmission: oligodendrocytes and Schwann cells sustain the saltatory conductance
of the electric stimuli by insulating specific regions of the axonal tracts, astrocytes provide neu-
rons with some already metabolized neurotransmitters and together with microglia participate in
information processing at the level of single synapses or neuronal networks (2). The contribution
of microglia to neuronal activity was initially suggested by the observation that multiple contacts
occur between microglial cells and neurons at the synaptic terminals (3). In fact, in the developing
and adult nervous system, microglia, owing to its phagocytic activity, can physically remodel
synapses in a neuronal activity-dependent manner by eliminating excessive or unused contacts
(synapse pruning) (4), leading to the formation and consolidation of rearranged synapses driven
by sensory experience (synapse maturation) (3, 5–8). In hippocampal neuron cultures, microglia
can sustain long-term potentiation (LTP) (9, 10), an observation supported in vivo by significant
learning and memory deficits in microglia-depleted mice (11). In pathological brain conditions
also the basal glutamatergic and GABAergic transmission can be regulated by microglia cells as a
consequence of the stimulatory effects of damaged cells-derived ATP on their secretion (12–15);
in fact, brain-derived neurotrophic factor (BDNF) secreted from ATP-stimulated cells can tune
both excitatory and inhibitory neuronal circuits activity and also support neuronal survival during
inflammation (16). In addition, extracellular ATP strongly induces the generation of microvesicles
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by plasma membrane shedding from responsive cells (17). In
this complex picture, microvesicles released by microglia have
been shown to cause an excitatory-inhibitory unbalance. They
stimulate spontaneous and evoked glutamate transmission in
excitatory neurons by facilitating presynaptic release probability
(18), while decrease spontaneous GABAergic tone (19). Potenti-
ation of excitatory transmission seems to reside in the capabil-
ity of microvesicles to interact with neurons and modulate the
levels of sphyngosine, which has been found to have a strong
impact on neuronal firing activity (20–22), by acting on the lipid
metabolizing enzyme acid sphingomyelinase (aSMase). Reduc-
tion of GABAergic transmission is instead mediated by endo-
cannabinoids, which are highly enriched inmicrovesicles, through
the activation of presynaptic CB1 receptors (19). Here, we will
review current knowledge on myeloid cells and their release of
microvesicles in neuroinflammatory disorders such as multiple
sclerosis (MS).
Myeloid Cells in MS
Myeloid cells, encompassing microglia, monocytes-derived
macrophages and resident-CNS macrophages, play an important
role in the pathogenesis of MS and its animal model experimental
autoimmune encephalomyelitis (EAE). MS and EAE, in fact,
are characterized by the rapid recruitment of blood-borne
monocytes, the reaction of resident microglia and perivascular
macrophages, along with the recruitment of T cells (23).
Many studies have demonstrated that reactive microglia and
macrophages can be found in white matter lesions (early and
late) and in gray matter subpial lesions (24). Macrophages
within CNS lesion sites are difficult to distinguish from reactive
microglia, since they both are amoeboid-shaped and express
the same antigenic markers. Many authors refer to these cells
collectively as macrophages/microglia or as mononuclear
phagocytes. The importance of these cells in the MS pathogenesis
is demonstrated by several EAE studies: a marked reduction in
disease severity is observed when reactive microglia/monocytes
are killed either by ganciclovir administration to EAE induced
in CD11b-HSV-TK mice (25), or using clodronate liposomes
(26). Moreover, inflammatory monocytes (CCR2+ and/or
Ly-6C high) have been shown to promote EAE progression,
while CCR2-deficient mice are resistant to EAE (24, 27, 28).
The monitoring of microglial reaction in vivo was made
possible by the discovery of the radiolabeled molecule 11C(R)-
PK11195177, a ligand for the benzodiazepine receptor whose
expression in the CNS is increased in reactive microglia (29).
A recent study showed correlation between clinical disability
and PK11195 PET binding in the cortex of MS patients (30).
Both MS and EAE are characterized by a dramatic increase in
bound radiolabel in both inflamed and normal appearing white
matter on MRI. The latter increase in 11C(R)-PK11195 binding
potentially indicates subtle microglial reaction, supporting
the hypothesis that microglia reaction underlies early tissue
damage preceding demyelination and lesion formation (31).
Microglia/macrophages have many different functions and
can act in either a beneficial or detrimental fashion in MS
pathogenesis. First of all, mononuclear phagocytes are involved
in demyelination and phagocytosis of the degraded myelin (32).
Inflammation in MS leads to a massive entry of blood-derived
macrophages into brain parenchyma. These cells transform
into foamy macrophages in the presence of myelin debris and
interact with invading T cells (23). At the same time, local
inflammatory stimuli lead to a rapid reaction of brain resident
microglia and macrophages, which transform into phagocytic
cells in the presence of debris. Morphological transformation of
myeloid cells also works in reverse: macrophages freshly recruited
from the blood stream to the CNS may adapt to the neural
environment and undergo remarkable structural remodeling,
gradually developing branched processes and transforming into
microglia-like ramified cells. Thus, both populations – resident
microglia and hematogenous macrophages – contribute to
the phagocytic removal of myelin and oligodendrocytes (23).
Mononuclear phagocytes are found in most – if not all – MS
lesions, and finding myelin degradation products engulfed within
tissue macrophages/microglia remains one of the most reliable
histological markers of active demyelination (33). Phagocytic
activity by macrophages and microglia in MS can be seen as
a double-edged sword; on the one hand, it is beneficial by
clearing cellular debris, but on other the hand, it is destructive
for CNS tissues (34, 35). In addition, microglial/macrophage
cells contribute to MS and EAE pathogenesis through antigen
presentation, expressing MHC class II and co-stimulatory
molecules (CD83/CD40) (23, 36). Microglia express all
known TLRs (TLR 1–13) and these receptors are pivotal
for the generation of neuro-immune responses (37–40).
Microglia/macrophages also promote inflammation and tissue
damage (i) by secretion of pro-inflammatory cytokines, reactive
oxygen intermediates, and proteinases, (ii) by release of soluble
factors that are chemotactic and activate other lymphocytes, and
(iii) by physically disrupting the local extracellular environment,
thereby facilitating leukocyte influx into the CNS and leading to
tissue damage (41). Microglia/macrophages can act as antigen
presenting cells and therefore re-prime or reactivate T cells in
lesion sites (34, 42). Although the above-mentioned studies
emphasize the negative contribution of microglial/macrophage
cells in MS or EAE pathology, there is evidence indicating
a protective function of these cells in EAE and MS. Indeed,
mononuclear phagocytes can inhibit the adaptive immune
responses in the CNS, by secreting anti-inflammatory cytokines
(IL-10 and TGFβ) or by expressing inhibitory molecules such as
PD-L1 (B7-h1) (43). Triggering receptor expressed on myeloid
cells-2 (TREM2), a specific membrane-bound receptor involved
in reducing inflammation and promoting phagocytosis, is
increased in the CSF of both progressive and relapsing–remitting
MS patients (24, 41, 44). Microglia/macrophages are also
capable of secreting neurotrophic factors such as BDNF,
insulin-like growth factor-1 (IGF-1), and neurotrophin 3 (NT3)
and thus may contribute in promoting neural survival and
neurogenesis (45, 46), although inducing the release of NO by
astrocytes (47). Mononuclear phagocytes have been shown to
have a beneficial role in EAE, as remyelination was impaired
after depletion of macrophages with clodronate liposomes
(48). However, the relevance of these findings to human
demyelinating diseases is still unclear. Thus, in MS, microglial
Frontiers in Neurology | www.frontiersin.org May 2015 | Volume 6 | Article 1112
Carandini et al. Microvesicles in MS
cells and macrophages may display both neurodestructive
and neuroprotective functions (35). Switching their function
from neurodestructive to neuroprotective may be beneficial
in preventing chronic demyelination and axonal loss and thus
preventing disease progression.
Microvesicles: Novel Biomarkers of CNS
Diseases
In multicellular organisms, communication between cells is a
fundamental process to guarantee adequate coordination among
different cell types within tissues and to exchange information.
Classical means of cell communication are represented by three
main mechanisms: (i) cell-to-cell contact-dependent signaling,
mediated by adhesion molecules and gap junctions; (ii) secre-
tion and diffusion of signaling molecules that can act on a
short distance target (paracrine signaling) or on a longer one
(endocrine signaling); (iii) synaptic signaling (typical of neurons)
in which neurons, through their axons, can reach distant target
cells and create with them a junction called “chemical synapse.”
In addition to these described processes, other mechanisms of
cell communication have recently attracted increasing interest:
tunneling nanotubes (49) and extracellular vesicles (EVs). Here,
we focus on EVs. EVs are spherical membrane vesicles het-
erogeneous in size (up to 1µm in diameter) and limited by a
lipid bilayer containing hydrophilic soluble components. EVs can
form either at the plasma membrane or in the lumen of internal
compartments and are secreted into the extracellular space. Irre-
spective of their origin, these vesicles contain cytosol and have
the same membrane topology of parental cells, exposing at their
outer surface the extracellular side of the bilayer of donor cells.
Because their membrane orientation is the same as that of the
donor cell, they can be considered to be miniature versions of
the donor cell (50). EVs are thought to function as shuttles for
the delivery of cargo between different cells within an organism
(51). Indeed, EVs carry receptors, bioactive lipids, proteins, and,
most importantly, nucleic acids, such as RNA and microRNA
(miRNA); thus, EVs may modify the phenotype and functions of
target cells (52). Nowadays, three types of EVs are distinguished
unanimously: exosomes, microvesicles (MVs, also called shed-
ding vesicles, ectosomes, shedding MVs, or microparticles), and
apoptotic bodies, also called apoptotic blebs or apoptotic vesicles
(50, 53, 54) (Figure 1). Exosomes are secreted membrane vesicles
(approximately 30–120 nm in diameter) formed intracellularly
and released from exocytosis of multivesicular bodies (55, 56),
whereas apoptotic bodies (approximately 500–4000 nm in diame-
ter) are released by dying/apoptotic cells (57) (Figure 1). MVs are
heterogeneous membrane vesicles (approximately 200–1500 nm
in diameter), which bud directly from the plasma membrane (58)
(Figure 1). All these different types of vesicles are present simul-
taneously in the extracellular environment of tissues (Figure 2).
We here focus on MVs. Upon vesciculation, released MVs can
both remain in the extracellular space in close proximity to the
cell of origin or diffuse in biological fluids (59). MVsmediate cell-
to-cell communication interaction with target cells by different
mechanism: (a) stimulation of target cells by acting as signal com-
plex, (b) transfer of surface receptors from one cell to another, (c)
FIGURE 1 | Electron microscopy and main features of microglial
exosomes and shed vesicles. Transmission electron microscopy of the
human CHME-5 microglial cell line exposed to ATP (500µM); massive
blebbing of the membrane occurs in a short time (5–7min). In this image,
multivesicular bodies containing exosomes are indicated in the solid squares,
while released shed vesicles are indicated in dashed squares. Corresponding
features are reported in the boxes on the right.
FIGURE 2 | ATP induces extensive blebbing and shedding of
myeloid-cell plasma membrane. A human microglia cell of the CHME-5
line exposed to ATP (500µM); the massive blebbing of the membrane occurs
in a short time (5–7min), witnessing the strength of the connections between
the purinergic signaling receptors activation and the cell surface dynamics.
delivery of proteins, mRNA, and miRNA, (d) vehicle mechanism
to transfer infectious particles (e.g., HIV, prions) (60). Growing
evidence indicates that MVs contribute to the pathogenesis of
cancer, inflammation, autoimmune, and cardiovascular disease
(61). Numbers of MVs in biological fluids seem to correlate with
the active phase of many diseases, thus MVs are currently under
investigation as possible biomarkers.
Microvesicles in Multiple Sclerosis
Several studies demonstrate that EVs (both MVs and exosomes)
play an active role during the pathogenesis of MS and EAE. MVs
from the brain endothelium have been shown to activate both
CD4+ and CD8+ T cells toward neural antigens in the absence
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of any other stimulatory signal and may represent the poten-
tial initial step of brain autoimmunity (62). Increased numbers
of MVs have been reported in the blood and in the CSF of
MS patients as compared to healthy controls. MVs have been
proposed to play a role in inflammatory progression and lesion
repair. Injection of microglial MVs into the brain of mice with
subclinical EAE recruits inflammatory cells to the injection site
(58). However, aSMase deficient mice, which are impaired in
MV production in microglia and astrocytes, are largely protected
from EAE, although these genetic mutant mice may have defects
also in other compartments relevant to the disease. MVs released
from BBB-endothelial cells, platelets, leukocytes, myeloid cells
(monocytes/macrophages/microglia), and astrocytes, are involved
in the pathogenesis of MS (63). The first step is the migra-
tion of inflammatory cells through the BBB. Endothelial MVs
carry metalloproteases that promote BBB disruption (64) and
molecules inducing endothelial activation (65). Endothelial MVs
can interact and form complexes with monocytes and activate
them (66). Also, activated T cells release MVs containing the
chemokine CCL5 and arachidonic acid, which recruite mono-
cytes and up-regulate ICAM-1 on endothelial cells and LFA1 and
Mac-1 on monocytes (63, 67). Platelet-derived MVs express on
their surface P-selectin, which binds to PSGL-1 and PECAM-
1 from lymphocytes by increasing the expression of integrins
such as α4β1 (VLA-4) (63). This process promotes the binding
of lymphocytes to the endothelium (68) and their transmigra-
tion into the CNS. Moreover, together with endothelial-derived
MVs, platelet-derived MVs fromMS patients have been shown to
increase the permeability of endothelial layers in vitro, suggesting
their involvement in the disruption of the BBB (69). In the CNS
compartment, MVs shed by myeloid cells contain components of
the inflammasome, such as IL1-β, MHC-II, and others (70).
Since apparently the level of MVs in biological fluids is asso-
ciated with the activation of cells involved in MS pathogenesis,
several authors have proposed them as plausible biomarkers.
The inconsistency of results produced so far depends mainly on
pre-analytical errors, technological issues related to MVs mea-
surement, ambiguity in EVs definition (MVs vs. exosomes), cor-
relation with clinical and paraclinical parameters such as disease
subtype and severity (EDSS), and MRI.
Concerning studies on CSF, Scolding et al. described, for the
first time, the presence of oligodendroglial MVs in the CSF of
patients with MS (71). More recently, our group revealed the
presence of increased levels of myeloid cells-derived MVs (Ib4+)
in the CSF of relapsing–remitting MS patients, compared with
healthy controls (58). Higher number of CSF MVs was especially
associated to acute disease phase, as compared to stable or chronic
phases. In fact,MVs counts in theCSF correlate linearlywith gad+
lesions at MRI. Accordingly, in EAE the concentration of CSF
MVs perfectly mirrors the course and severity of both relapsing
and chronic EAE peaking at onset and during clinical relapses,
and decreasing in the chronic phase of the disease. When we
investigated MVs as a possible biomarker in MS, based on ROC
analysis, we obtained a sensitivity of 85% and specificity of 100%
for distinguishing clinically isolated syndrome (CIS) patients from
healthy controls, and a sensitivity of 82% and specificity of 82%
for differentiating stable (relapse-free patients) from relapsingMS
patients (58). Unfortunately, studies of MVs in the CSF of MS
patients are difficult to perform, both because of the scarcity of
material usually available, and because patients for ethical con-
cerns can not perform serial lumbar punctures to assess MVs’
trend over time. For these reasons, many studies have focused
on the evaluation of MVs’ levels in the peripheral blood, trying
to correlate their number with some clinical and instrumental
parameters.
CD31+ endothelial MVs, identified in plasma samples by
FACS, have been associated to clinical and neuroradiological
exacerbation of MS, while CD51+ endothelial MVs have been
found elevated in both relapsing and remitting MS patients as
compared to controls (65). The same group has confirmed their
findings in 2004, further describing that most endothelial MVs
can be detected in the blood in the form of conjugates with other
cells, especially monocytes (66), while described that, similarly
to stroke, platelet-derived MVs, despite elevated in the plasma
of MS patients as compared to controls, display a reduced dis-
criminating power between health and disease (68). Jimenez et al.
(72) reported an increase of CD54+ and CD62E+ endothelial
MVs in the plasma of MS patients during relapse compared to
remission. Sáenz-Cuesta et al. (73) demonstrated a significant
difference also in CD61+ (platelet marker), CD45+ (lymphocyte
marker), and CD14+ (monocyte marker) MVs counts in samples
from MS patients compared to those from healthy controls. MVs
were especially high in relapsing–remitting patients, while sec-
ondary progressive MS patients were similar to healthy controls.
PlasmaMVs levels in this work appear to reflect short-term active
inflammation rather than disease severity, as measured by EDSS,
or disease duration or patients age (73).
Considering MVs as biomarkers of therapeutic efficacy in MS,
Jimenez et al. (72) report that IFN-β 1b reduces the release of
endothelial MVs induced by plasma from MS patients. IFN-β
1b also reduces monocyte–endothelial MVs complex formation
and transendothelial migration in vitro (72). Sheremata et al.
(74) report the ability of IFN-beta1a to reduce the number of
CD31+ endothelial MVs in plasma of relapsing–remitting MS
patients as early as threemonths after treatment initiationwithout,
however, any correlation with MRI activity. Lowery-Nordberg
et al. performed a prospective study, measuring changes in plasma
of CD31+, CD146+, and CD54/ICAM-1+ endothelial MVs in
16 patients with RR-MS before and after 3, 6, and 12months
of therapy with interferonbeta1a (Rebif44®). They found that
plasma levels of CD31+, and CD54+ – and not CD146+ –
endothelial MVs were significantly reduced by treatment with
IFNβ. Moreover, they demonstrated a significant association
between the decrease in plasma levels of MVs and the decrease
in the number and volume of contrast enhancing T1-weigthed
MRI lesions (75). On the contrary, in a recent study measur-
ing plasma platelet MVs, lymphocyte MVs, and monocyte MVs,
Sáenz-Cuesta et al. (73) reported, using flow cytometry (prob-
ably focusing on MVs), higher counts of all three MVs sub-
types in IFN-β and natalizumab-treated patients (73). Dawson
et al. demonstrated that fingolimod inhibits aSMase (76), the
enzyme that controls MVs production (17). In our work (58),
we hypothesized that fingolimod might inhibit myeloid cells-
derivedMVs shedding from reactivemicroglia. Indeed, EAEmice
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treated with fingolimod displayed a reduction of CSF myeloid
MVs to baseline levels. Through this mechanism, fingolimod
may inhibit the spreading of inflammatory signals throughout the
brain parenchima (58).
Conclusion
There is still incomplete information on the role of microvesicles
in MS, but available evidence points to a relevant role, both
in spreading pro-inflammatory signals and in altering neuronal
functions. The potentially relevant role in the pathogenesis of the
disease, underlines how microvesicles, especially those released
by microglia/macrophages, may represent precious biomarkers,
although for the moment they only can indicate, for example,
the presence of microglial reaction, but are not linked to a spe-
cific disease. Involvement in pathogenic mechanisms may suggest
also microvesicles as possible therapeutic targets. The develop-
ment of adequate technology for the detection and analysis of
microvesicles will provide in the near future the answer to the
questions posed in this review and reveal if new and valuable
information on MS is indeed enveloped in these microscopic
nanoparticles.
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